Stock Evaluator: BioNexus Gene Lab Corp. (BGLC)

BioNexus Gene Lab Corp. BGLC

$1.32 0.00 0.00%
July 31, 2026 3:58:57 PM EST November 10, 2021 Volume: 10,006
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Industrials Trading Companies & Distributors

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company’s products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

Commentary & Analysis


Financial Summary

Share Statistics BGLC Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3.2 $4,922.5 2%
Shares Out (Mil) 2.4 37.8 8%
Institutional Ownership 0.4% 63.8% 2%
Float (Mil) 1.8 47.9 4%
Beta 2.19 0.97 94%
Avg Daily Volume (000s) 14 235 19%
Price Change
(52-week)
(70.4%) 80.3% 9%
Growth BGLC Industry
Median
Percentile
(All Stocks)
Sales (5yr) (8.3%) 8.9% 6%
Net Income (5yr) (36.4%) 11.1% 11%
EPS (5yr) (26.7%) 11.8% 10
Dividends (5yr) 0.0% 2.8% 0%
Cash Flow (5yr) (16.0%) (13.7%) 46%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials BGLC Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $5 $3,347 6%
Net Income (TTM) (Mil) ($3) $137 35%
EPS (TTM) ($1.444) $1.400 18%
Operating Cash Flow (TTM) (Mil) ($1) $302 30%
Net Cash Flow (TTM) (Mil) $0 $3 45%
Long-Term Debt (Q1) (Mil) $0 $640 12%
Enterprise Value (Q1) (Mil) $3 $6,212 4%
Valuation BGLC Industry
Median
Percentile
(All Stocks)
P/B 0.39 2.65 6%
P/E na 25.8 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.4 na
Ratios BGLC Industry
Median
Percentile
(All Stocks)
Gross Margin 14.0% 27.5% 13%
Net Margin (54.7%) 4.0% 11%
ROA (31.4%) 4.5% 16%
ROE (36.6%) 12.2% 18%
Liabilities to Assets 10.5% 57.0% 6%
F-Score 3 5 19%

BioNexus Gene Lab Corp. did not pass any screens on 7/31/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors